1ody: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1ody.jpg|left|200px]] | [[Image:1ody.jpg|left|200px]] | ||
'''HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130''' | {{Structure | ||
|PDB= 1ody |SIZE=350|CAPTION= <scene name='initialview01'>1ody</scene>, resolution 2.0Å | |||
|SITE= | |||
|LIGAND= <scene name='pdbligand=LP1:4-[2-(2-ACETYLAMINO-3-NAPHTALEN-1-YL-PROPIONYLAMINO)-4-METHYL-PENTANOYLAMINO]-3-HYDROXY-6-METHYL-HEPTANOIC ACID [1-(1-CARBAMOYL-2-NAPHTHALEN-1-YL-ETHYLCARBAMOYL)-PROPYL]-AMIDE'>LP1</scene> | |||
|ACTIVITY= [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] | |||
|GENE= | |||
}} | |||
'''HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130''' | |||
==Overview== | ==Overview== | ||
| Line 7: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
1ODY is a [ | 1ODY is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_type_1_(isolate_hxb2) Human immunodeficiency virus type 1 (isolate hxb2)]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1ODY OCA]. | ||
==Reference== | ==Reference== | ||
Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV., Kervinen J, Lubkowski J, Zdanov A, Bhatt D, Dunn BM, Hui KY, Powell DJ, Kay J, Wlodawer A, Gustchina A, Protein Sci. 1998 Nov;7(11):2314-23. PMID:[http:// | Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV., Kervinen J, Lubkowski J, Zdanov A, Bhatt D, Dunn BM, Hui KY, Powell DJ, Kay J, Wlodawer A, Gustchina A, Protein Sci. 1998 Nov;7(11):2314-23. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/9827997 9827997] | ||
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Human immunodeficiency virus type 1 (isolate hxb2)]] | [[Category: Human immunodeficiency virus type 1 (isolate hxb2)]] | ||
| Line 20: | Line 29: | ||
[[Category: Zdanov, A.]] | [[Category: Zdanov, A.]] | ||
[[Category: LP1]] | [[Category: LP1]] | ||
[[Category: | [[Category: aid]] | ||
[[Category: aspartic protease]] | [[Category: aspartic protease]] | ||
[[Category: hiv]] | [[Category: hiv]] | ||
| Line 26: | Line 35: | ||
[[Category: retrovirus]] | [[Category: retrovirus]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 13:09:30 2008'' | ||
Revision as of 14:09, 20 March 2008
| |||||||
| , resolution 2.0Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | |||||||
| Activity: | HIV-1 retropepsin, with EC number 3.4.23.16 | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
OverviewOverview
One of the major problems encountered in antiviral therapy against AIDS is the emergence of viral variants that exhibit drug resistance. The sequences of proteases (PRs) from related retroviruses sometimes include, at structurally equivalent positions, amino acids identical to those found in drug-resistant forms of HIV-1 PR. The statine-based inhibitor LP-130 was found to be a universal, nanomolar-range inhibitor against all tested retroviral PRs. We solved the crystal structures of LP-130 in complex with retroviral PRs from HIV-1, feline immunodeficiency virus, and equine infectious anemia virus and compared the structures to determine the differences in the interactions between the inhibitor and the active-site residues of the enzymes. This comparison shows an extraordinary similarity in the binding modes of the inhibitor molecules. The only exceptions are the different conformations of naphthylalanine side chains at the P3/P3' positions, which might be responsible for the variation in the Ki values. These findings indicate that successful inhibition of different retroviral PRs by LP-130 is achieved because this compound can be accommodated without serious conformational differences, despite the variations in the type of residues forming the active-site region. Although strong, specific interactions between the ligand and the enzyme might improve the potency of the inhibitor, the absence of such interactions seems to favor the universality of the compound. Hence, the ability of potential anti-AIDS drugs to inhibit multiple retroviral PRs might indicate their likelihood of not eliciting drug resistance. These studies may also contribute to the development of a small-animal model for preclinical testing of antiviral compounds.
About this StructureAbout this Structure
1ODY is a Single protein structure of sequence from Human immunodeficiency virus type 1 (isolate hxb2). Full crystallographic information is available from OCA.
ReferenceReference
Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV., Kervinen J, Lubkowski J, Zdanov A, Bhatt D, Dunn BM, Hui KY, Powell DJ, Kay J, Wlodawer A, Gustchina A, Protein Sci. 1998 Nov;7(11):2314-23. PMID:9827997
Page seeded by OCA on Thu Mar 20 13:09:30 2008